Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab Biosimilars
May 16th 2022, 1:05pm
VideoWhile 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.